{"database":"ecrin-mdr-crc","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":0,"searchCount":0},"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"condition":["Colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/89220"],"location":["China"],"study_start_month":["7"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"citation_count":["0"],"additional_accession":[]},"is_claimable":false,"name":"Stereotactic ablative radiotherapy in combination with bevacizumab and anti-PD-L1 in patients with liver metastases from colorectal cancer of MSS: a prospective, single-arm, single-center, exploratory clinical trial","description":"Interventions: Group of colorectal cancer:SBRT+bevacizumab+Envafolimab\nPrimary outcome(s): Objective remission rate of disease\nStudy Design: Single arm","dates":{"creation":"2023-07-15"},"accession":"89220","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2300073116"]}}